Lisata Therapeutics (LSTA) Stock Overview
A clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
LSTA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
LO
Fair Value from
US$7.675.4% undervalued intrinsic discount
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeLisata Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.23 |
| 52 Week High | US$5.07 |
| 52 Week Low | US$1.81 |
| Beta | 0.81 |
| 1 Month Change | -35.40% |
| 3 Month Change | -28.85% |
| 1 Year Change | 36.01% |
| 3 Year Change | -1.46% |
| 5 Year Change | -84.62% |
| Change since IPO | -99.90% |
Recent News & Updates
Narrative Update • May 02
LSTA: Higher Growth Outlook Will Offset Going Concern Liquidity Risk
Analysts have reset their 12 month price target for Lisata Therapeutics from $11.33 to $9.50, reflecting updated assumptions for revenue growth, profit margin, and a lower forward P/E multiple in their models. What's in the News Lisata Therapeutics filed its 10 K on March 12, 2026 for the period ending December 31, 2025, providing updated audited financial statements and disclosures for the year.
Narrative Update • Apr 17
LSTA: Kuva Cash Deal Will Support Future Upside Potential
Analysts have adjusted their price target on Lisata Therapeutics to $15.00 from $15.00, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E while referencing the recent downgrade highlighted in Street research. Analyst Commentary Bullish analysts looking at Lisata Therapeutics are framing the updated US$15.00 price target within a wider debate about how quickly the company can execute on its pipeline and how much of that potential is already reflected in the shares.Narrative Update • Apr 03
LSTA: Kuva Cash Deal And Pipeline Milestones Will Support Future Upside Potential
Analysts have reduced their price target on Lisata Therapeutics to $15.00, citing updated assumptions on the discount rate, revenue growth, profit margin, and future P/E following recent research that included a downgrade at Brookline. Analyst Commentary Recent research points to a more cautious stance on Lisata Therapeutics, yet there are still several areas that bullish analysts highlight as potential positives for long term holders.Narrative Update • Mar 20
LSTA: Brookline Downgrade And Kuva Cash Deal Will Reset Upside Expectations
Analysts have revised their price target for Lisata Therapeutics to $15.00, reflecting updated assumptions around revenue growth, profit margins, and a lower future P/E, as outlined in recent Street research. Analyst Commentary Recent Street research around Lisata Therapeutics highlights a wide range of views, with some investors focusing on execution risks and others pointing to upside potential if key assumptions play out as expected.Narrative Update • Mar 05
LSTA: Brookline Downgrade And Acquisition Offer Will Reset Expectations For Upside
Analysts have adjusted their price target on Lisata Therapeutics to $15.00. The change reflects updated assumptions around revenue growth, profit margins and future P/E expectations following recent research, including a downgrade at Brookline.Recent updates
Narrative Update • May 02
LSTA: Higher Growth Outlook Will Offset Going Concern Liquidity Risk
Analysts have reset their 12 month price target for Lisata Therapeutics from $11.33 to $9.50, reflecting updated assumptions for revenue growth, profit margin, and a lower forward P/E multiple in their models. What's in the News Lisata Therapeutics filed its 10 K on March 12, 2026 for the period ending December 31, 2025, providing updated audited financial statements and disclosures for the year.Narrative Update • Apr 17
LSTA: Kuva Cash Deal Will Support Future Upside Potential
Analysts have adjusted their price target on Lisata Therapeutics to $15.00 from $15.00, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E while referencing the recent downgrade highlighted in Street research. Analyst Commentary Bullish analysts looking at Lisata Therapeutics are framing the updated US$15.00 price target within a wider debate about how quickly the company can execute on its pipeline and how much of that potential is already reflected in the shares.Narrative Update • Apr 03
LSTA: Kuva Cash Deal And Pipeline Milestones Will Support Future Upside Potential
Analysts have reduced their price target on Lisata Therapeutics to $15.00, citing updated assumptions on the discount rate, revenue growth, profit margin, and future P/E following recent research that included a downgrade at Brookline. Analyst Commentary Recent research points to a more cautious stance on Lisata Therapeutics, yet there are still several areas that bullish analysts highlight as potential positives for long term holders.Narrative Update • Mar 20
LSTA: Brookline Downgrade And Kuva Cash Deal Will Reset Upside Expectations
Analysts have revised their price target for Lisata Therapeutics to $15.00, reflecting updated assumptions around revenue growth, profit margins, and a lower future P/E, as outlined in recent Street research. Analyst Commentary Recent Street research around Lisata Therapeutics highlights a wide range of views, with some investors focusing on execution risks and others pointing to upside potential if key assumptions play out as expected.Narrative Update • Mar 05
LSTA: Brookline Downgrade And Acquisition Offer Will Reset Expectations For Upside
Analysts have adjusted their price target on Lisata Therapeutics to $15.00. The change reflects updated assumptions around revenue growth, profit margins and future P/E expectations following recent research, including a downgrade at Brookline.Narrative Update • Feb 18
LSTA: Pending Kuva Acquisition And Contingent Rights Will Support Future Upside
Analysts have reduced their price target on Lisata Therapeutics from $13.00 to approximately $11.33. They cited updated assumptions around fair value, discount rate, long-term revenue growth, profit margins, and future P/E multiples following recent changes in research coverage.Narrative Update • Feb 04
LSTA: Acquisition Offer And Downgrade Reset Expectations Before Potential Upside
Analysts have trimmed their price target on Lisata Therapeutics from US$15 to US$15.00, reflecting updated assumptions around revenue growth, profit margins, discount rates, and a higher future P/E multiple following recent research, including a downgrade from Brookline. Analyst Commentary Despite the recent trim in the headline price target, bullish analysts still see room for upside if Lisata executes on its plans and delivers against current expectations.Narrative Update • Jan 21
LSTA: Refined Risk Assumptions Will Support Future Upside Despite Recent Downgrade
Analysts have slightly reduced their fair value estimate to US$13.00, citing modest adjustments to the discount rate, long term profit margin expectations, and a lower implied future P/E as they reassess Lisata Therapeutics following a recent downgrade in Street research. Analyst Commentary Bullish Takeaways Bullish analysts view the revised US$13.00 fair value as still reflecting upside potential, provided that execution on key clinical and operational milestones tracks internal expectations.Narrative Update • Jan 07
LSTA: Improved Profitability Assumptions Will Support Strong Future Upside Potential
Analysts have modestly lifted their price target for Lisata Therapeutics, citing slightly improved profit margin assumptions at 16.24% and a lower future P/E estimate of 103.37x as key drivers of their updated valuation. Valuation Changes Fair Value: Remains unchanged at 13.0, suggesting the overall valuation anchor has been kept steady.Narrative Update • Dec 24
LSTA: Upcoming Pancreatic Cancer Data And Catalent Deal Will Drive Shares
Analysts have reduced their price target on Lisata Therapeutics from 32.00 dollars to 15.00 dollars, citing higher discount rates despite stronger projected revenue growth, improved profit margins, and a materially lower future price-to-earnings multiple. What's in the News Lisata Therapeutics and Catalent signed a global product license agreement granting Catalent non exclusive worldwide rights to incorporate certepetide into antibody drug conjugates using its SMARTag technology platform, including the ability to partner with third parties (Key Developments) Under the Catalent collaboration, Lisata is eligible for more than 10 million dollars in tiered study initiation milestone payments plus revenue sharing on future product sales and partnerships (Key Developments) Certepetide, Lisata's proprietary iRGD cyclic peptide, has shown favorable safety, tolerability, and clinical activity in trials aimed at improving the effectiveness of standard of care chemotherapy for pancreatic cancer and other solid tumors (Key Developments) Certepetide has received multiple regulatory designations, including Fast Track and Orphan Drug Designation for pancreatic cancer in the U.S. and E.U., Orphan Drug Designation for glioma and osteosarcoma in the U.S., and Rare Pediatric Disease Designation for osteosarcoma in the U.S. (Key Developments) Preliminary data from the PDAC cohort of the Phase 1/2a CENDIFOX trial of certepetide plus FOLFIRINOX based therapies will be presented at the AACR Special Conference in Cancer Research on Advances in Pancreatic Cancer Research on September 29, 2025, in Boston, Massachusetts (Key Developments) Valuation Changes Fair Value Estimate: Reduced significantly from 32 dollars to 15 dollars per share, reflecting a more conservative assessment despite stronger fundamentals.Narrative Update • Dec 09
LSTA: Upcoming Cancer Trial Milestones Will Drive Strong Upside Potential
Analysts have nudged their price target on Lisata Therapeutics slightly higher to 13.00 dollars from 13.00 dollars, reflecting modest adjustments to the discount rate and long-term valuation assumptions, despite largely unchanged growth and margin expectations. What's in the News Lisata Therapeutics and Catalent entered a global product license agreement granting Catalent worldwide, non exclusive rights to use certepetide in antibody drug conjugates developed on its SMARTag platform, with Lisata eligible for over 10 million dollars in tiered milestone payments plus revenue sharing on future sales and partnerships (Key Developments) Certepetide, Lisata's proprietary internalizing RGD cyclic peptide, will be evaluated by Catalent as a payload across multiple ADCs targeting difficult to treat diseases.Narrative Update • Nov 25
LSTA: Global Licensing Milestones And Trial Results Will Drive Future Upside
Analysts have raised their price target for Lisata Therapeutics slightly, increasing it from $13.00 to $13.00 per share. This reflects updated projections for profitability and valuation metrics.Narrative Update • Nov 09
LSTA: Milestone Payments And Clinical Progress Will Drive Future Upside
Analysts have revised their price target for Lisata Therapeutics from $20.67 to $13.00, citing updated financial assumptions and outlook. What's in the News Lisata Therapeutics and Catalent have entered a global product license agreement, granting Catalent non-exclusive rights to develop and commercialize bioconjugate products containing certepetide using the SMARTag technology platform.Analysis Article • Aug 13
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Analysis Article • Apr 26
We Think Lisata Therapeutics (NASDAQ:LSTA) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Narrative • Apr 14
Certepetide Advancements And Regulatory Approvals Will Set New Care Standards
Advancements in certepetide and regulatory achievements could expedite market entry, fostering revenue growth and enhancing treatment standards.Analysis Article • Dec 24
Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Analysis Article • Jul 15
Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analysis Article • Mar 22
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Sep 15
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Sep 14
Caladrius rallies on approval of merger, name change to Lisata Therapeutics
Caladrius Biosciences (NASDAQ:CLBS) announced that its stockholders approved all of the merger-related proposals by Caladrius and Cend Therapeutics, and the transactions contemplated thereby, including the Merger and the issuance of shares of Caladrius’ common stock to Cend’s stockholders. Subsequent to the stockholders’ approval, the Caladrius Board of Directors approved a reverse stock split of Caladrius’ common stock at a ratio of one new share for every fifteen shares outstanding. The reverse stock split will become effective today, Sept. 14, 2022, at 5:00pm EST. The consolidated common shares for the combined company, which will be renamed Lisata Therapeutics, are expected to commence trading on Nasdaq under the symbol “LSTA” on Sept. 15, 2022, at 9:30am EST. CLBS +39.28% premarket to $0.71.Seeking Alpha • Aug 04
Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01
Caladrius Biosciences press release (NASDAQ:CLBS): Q2 GAAP EPS of -$0.11 beats by $0.01. As of June 30, 2022, the company had cash, cash equivalents and marketable securities of approximately $73 million. Merger with Cend Therapeutics remains on track to close in Q3.Analysis Article • May 02
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...Analysis Article • Jan 05
We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • May 09
Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analysis Article • Nov 30
Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Shareholder Returns
| LSTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.5% | 1.2% | 2.1% |
| 1Y | 36.0% | 41.9% | 30.6% |
Return vs Industry: LSTA underperformed the US Biotechs industry which returned 41.9% over the past year.
Return vs Market: LSTA exceeded the US Market which returned 31% over the past year.
Price Volatility
| LSTA volatility | |
|---|---|
| LSTA Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LSTA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LSTA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 21 | Dave Mazzo | www.lisata.com |
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Lisata Therapeutics, Inc. Fundamentals Summary
| LSTA fundamental statistics | |
|---|---|
| Market cap | US$29.45m |
| Earnings (TTM) | -US$16.59m |
| Revenue (TTM) | US$170.00k |
171.6x
P/S Ratio-1.8x
P/E RatioIs LSTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LSTA income statement (TTM) | |
|---|---|
| Revenue | US$170.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$170.00k |
| Other Expenses | US$16.76m |
| Earnings | -US$16.59m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.84 |
| Gross Margin | 100.00% |
| Net Profit Margin | -9,756.47% |
| Debt/Equity Ratio | 0% |
How did LSTA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/07 16:52 |
| End of Day Share Price | 2026/05/07 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lisata Therapeutics, Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jan Wald | Benchmark Company |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Kumaraguru Raja | Brookline Capital Markets |